Sugi Predict

Sugi Predict / Compounds / SCHEMBL6803149

SCHEMBL6803149

SCHEMBL6803149

N[C@@H](Cc1ccccc1)C(=O)OC1CCCCC1

nearest known ligand 0.62

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ TYR P14679 1/20 0.62
▸ ALPI P09923 1/20 0.51
▸ PKM P14618 1/20 0.51
▸ PTGS1 P23219 1/20 0.51
▸ XIAP P98170 1/20 0.51
▸ SLC7A5 Q01650 1/20 0.51
▸ DPP4 P27487 3/20 0.46
▸ DPP8 Q6V1X1 2/20 0.46
▸ DPP9 Q86TI2 2/20 0.46
▸ DPP7 Q9UHL4 2/20 0.46
▸ FAP Q12884 1/20 0.46
▸ SLC15A1 P46059 1/20 0.45
▸ HDAC8 Q9BY41 2/20 0.44
▸ ANPEP P15144 2/20 0.44
▸ ERAP2 Q6P179 2/20 0.44
▸ LTA4H P09960 1/20 0.43
▸ F2 P00734 1/20 0.43
▸ PRSS1 P07477 1/20 0.43
▸ ACE P12821 1/20 0.43
▸ CTSC P53634 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22375034 1.00 TYR (0.62) TYRALPIPKMPTGS1XIAP
SCHEMBL25769168 1.00 TYR (0.62) TYRALPIPKMPTGS1XIAP
SCHEMBL22375169 1.00 TYR (0.62) TYRALPIPKMPTGS1XIAP
SCHEMBL7782897 1.00 TYR (0.62) TYRALPIPKMPTGS1XIAP
SCHEMBL23642931 1.00 TYR (0.62) TYRALPIPKMPTGS1XIAP
SCHEMBL23643091 1.00 TYR (0.62) TYRALPIPKMPTGS1XIAP
Hydrochloric Acid SCHEMBL27841329 0.99 TYR (0.61) TYRALPIPKMPTGS1XIAP
SCHEMBL7114295 0.98 TYR (0.64) TYRALPIPKMPTGS1XIAP
SCHEMBL1491546 0.98 TYR (0.64) TYRALPIPKMPTGS1XIAP
Hydrochloric Acid SCHEMBL17707256 0.97 TYR (0.62) TYRALPIPKMPTGS1XIAP

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240092849-A1 SELECTIVE MCL-1 BINDING PEPTIDES MASSACHUSETTS INSTITUTE OF TECHNOLOGY 2024-03-21 — — US disclosed
US-20210363207-A1 SELECTIVE MCL-1 BINDING PEPTIDES MASSACHUSETTS INSTITUTE OF TECHNOLOGY 2021-11-25 — — US disclosed
US-20210138077-A1 SELECTIVE DRUG RELEASE FROM INTERNALIZED CONJUGATES OF BIOLOGICALLY ACTIVE COMPOUNDS SEAGEN INC. 2021-05-13 — — US disclosed
US-20190077840-A1 SELECTIVE MCL-1 BINDING PEPTIDES NATIONAL INSTITUTES OF HEALTH 2019-03-14 — — US disclosed
CN-107530405-A Insulin analogs containing glucose-regulated conformational converters 卡斯西部储备大学 2018-01-02 — — CN disclosed
WO-2017075349-A2 SELECTIVE MCL-1 BINDING PEPTIDES MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) 2017-05-04 — — WO disclosed
CN-102260246-A Low-toxicity CB1 receptor inhibitor, preparation method thereof and application thereof in preparation of medicaments for drug abstention, weight reduction or diabetes treatment — 2011-11-30 — — CN disclosed
US-6790834-B1 Cytostatic agents BRITISH BIOTECH PHARMACEUTICALS, LTD. (GB) 2004-09-14 — — US disclosed
US-6462023-B1 SUCH AS 2-HYDROXY-HYDROXYCARBAMOYL-METHYL)-4-METHYL-PENTANOYLAMINE)-2-PHENYL -ETHANOIC ACID CYCLOPENTYL ESTER; INHIBITING HYPERPROLIFERATIVE TUMOURGENIC CELLS SUCH AS MELANOMA AND/OR LYMPHOMA CELLS BRITISH BIOTECH PHARMACEUTICALS, LTD. (GB) 2002-10-08 — — US disclosed
EP-0925278-B1 CYTOSTATIC HYDROXAMIC ACID DERIVATIVES BRITISH BIOTECH PHARM (GB) 2002-07-17 — — EP disclosed
US-6218563-B1 Cyanophosphonamides and method for preparation MONSANTO COMPANY 2001-04-17 — — US disclosed
US-6169075-B1 ANTITUMOR AGENT INHIBITING THE PROLIFERATION OF A RANGE OF RAPIDLY DIVIDING TUMOUR CELLS LIKE MELANOMA AND/OR LYMPHOMA CELLS BRITISH BIOTECH PHARMACEUTICALS LIMITED (GB) 2001-01-02 — — US disclosed
WO-2000032611-A1 CYANOPHOSPHONAMIDES AND METHOD FOR PREPARATION MONSANTO TECHNOLOGY LLC (US) 2000-06-08 — — WO disclosed
CN-1230175-A Cytostatic hydroximic acid derivatives BRITISH BIOTECH PHARM (GB) 1999-09-29 — — CN disclosed
EP-0925278-A1 CYTOSTATIC HYDROXAMIC ACID DERIVATIVES BRITISH BIOTECH PHARMACEUTICALS LIMITED (GB) 1999-06-30 — — EP disclosed
US-5843941-A Ras farnesyl transferase inhibitors GENENTECH, INC. (US) 1998-12-01 — — US disclosed
WO-1998011063-A1 CYTOSTATIC HYDROXAMIC ACID DERIVATIVES BRITISH BIOTECH PHARMACEUTICALS LIMITED (GB) 1998-03-19 — — WO disclosed
EP-0763537-A2 Non-peptidyl Ras farnesyl transferase inhibitors GENENTECH, INC. (US) 1997-03-19 — — EP disclosed
EP-0698015-A1 PREPARATION OF N-CYANODITHIOIMINO-CARBONATES AND 3-MERCAPTO-5-AMINO-1H-1,2,4-TRIAZOLE GENENTECH, INC. (US) 1996-02-28 — — EP disclosed
WO-1994026723-A2 ras FARNESYL TRANSFERASE INHIBITORS GENENTECH, INC. (US) 1994-11-24 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210138077-A1 SELECTIVE DRUG RELEASE FROM INTERNALIZED CONJUGATES OF BIOLOGICALLY ACTIVE COMPOUNDS CTSB, CTSE, CTSZ TYR 1347/4885ALPI 1036/4885PKM 2851/4885
US-20190077840-A1 SELECTIVE MCL-1 BINDING PEPTIDES MCL1, BCL2L11, BCL2L1 TYR 4782/4885ALPI 4653/4885PKM 4138/4885
US-20240092849-A1 SELECTIVE MCL-1 BINDING PEPTIDES MCL1, BCL2L11, BCL2L1 TYR 4782/4885ALPI 4653/4885PKM 4138/4885
US-20210363207-A1 SELECTIVE MCL-1 BINDING PEPTIDES MCL1, BCL2L11, BCL2L1 TYR 4782/4885ALPI 4653/4885PKM 4138/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.